Yayınlar & Eserler

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity

Turanll S., Nalbat E., Lengerli D., İbiş K., Güntekin Ergün S., Akhan Güzelcan E., et al.
ACS Omega , cilt.7, sa.41, ss.36206-36226, 2022 (SCI-Expanded) identifier identifier identifier

Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.221, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

CROssBAR: comprehensive resource of biomedical relations with knowledge graph representations.

DOĞAN T., Atas H., Joshi V., ATAKAN A., Rifaioglu A. S., NALBAT E., et al.
Nucleic acids research , cilt.49, sa.16, 2021 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles.

Unal O., Akkoc Y., Kocak M., Nalbat E., Dogan-Ekici A., Yagci A., et al.
Journal of nanobiotechnology , cilt.18, ss.65, 2020 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations

RİFAİOĞLU A. S., NALBAT E., Atalay V., Martin M. J., Cetin-Atalay R., DOĞAN T.
CHEMICAL SCIENCE , cilt.11, sa.9, ss.2531-2557, 2020 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.

ÇALIŞKAN B., Sinoplu E., Ibis K., Guzelcan E. A., Atalay R. C., BANOĞLU E.
Journal of enzyme inhibition and medicinal chemistry , cilt.33, sa.1, ss.1352-1361, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

Diğer Dergilerde Yayınlanan Makaleler

Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools

Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., et al.
JOURNAL OF GASTROINTESTINAL CANCER , cilt.52, sa.4, ss.1266-1276, 2021 (ESCI) identifier identifier identifier

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

Exploring early markers of fibrosis progression in metabolic dysfunction–associated steatotic liver disease in Turkiye

KAHRAMAN D. C., NALBAT E., ATALAY R., İDİLMAN R.
AASLD-TASL Connect Meeting 2024, İzmir, Türkiye, 16 - 17 Şubat 2024

Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.
4th Open Research Day, Türkiye, 01 Aralık 2023

Exploring novel vicinal diaryl-substituted isoxazole and pyrazole derivatives as cytotoxic compounds for targeting breast cancer: Mechanisms and therapeutic potential

NALBAT E., GÜNTEKİN ERGÜN S., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.
XVIII. Tıbbi Biyoloji ve Genetik Kongresi, Ankara, Türkiye, 26 - 29 Ekim 2023

Breaking Barriers in Cancer Treatment: Unleashing the Power of Drug Repurposing

NALBAT E.
3rd International Multidisciplinary Cancer Research Congress, İstanbul, Türkiye, 7 - 09 Eylül 2023

Network-based drug repurposing approach identifies novel drugs and drug combinations against HCC

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 28 - 29 Nisan 2023

Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma

Nalbat E., Tunçbağ N., Atalay R.
15th International Symposium on Health Informatics and Bioinformatics (HIBIT), Mersin, Türkiye, 20 - 21 Ekim 2022, ss.1-2

Synthesis and Biological Evaluation of Novel Isoxazole-Piperazine Hybrids as Potential Anticancer Agents with Inhibitory Effects on Liver Cancer Stem Cells

İbiş K., Nalbat E., Çalışkan B., Atalay R., Banoğlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.58-61

BAZI VİSİNAL DİARİL HETEROSİKLİK BİLEŞİKLERİN ANTİKANSER AKTİVİTELERİNİN ARAŞTIRILMASI

Turanlı S., Nalbat E., Akhan Güzelcan E., Atalay R., Çalışkan B., Banoğlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.40-42

Identification of undefined off-targets of novel drugs and drug combinations with network-based in silico modeling and in vitro validation in hepatocellular carcinoma

Nalbat E., Tunçbağ N., Atalay R.
EACR 2022 Annual Meeting, Sevilla, İspanya, 20 - 23 Haziran 2022, ss.3-4

Anticancer activity of novel vicinal diaryl isoxazole compounds in hepatocellular carcinoma

Nalbat E., Akhan Güzelcan E., Turanlı S., Lengerli D., Çalışkan B., Banoğlu E., et al.
EASL Liver Cancer Summit 2022, 3 - 04 Şubat 2022, ss.137-138

Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells

NALBAT E., İBİŞ K., ÇALIŞKAN B., BANOĞLU E., ATALAY M. V., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 15 Ocak 2022, ss.5-6

In vitro validation of drug-target interactions revealed in silico by Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning (CROssBAR) in HCC

NALBAT E., RİFAİOĞLU A. S., DOĞAN T., Martin M. J., Cetin-Atalay R., ATALAY M. V.
AACR Annual Meeting, ELECTR NETWORK, 22 - 24 Haziran 2020, cilt.80 identifier

Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity

TURANLİ S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., et al.
8th International Drug Chemistry Conference, 27 Şubat - 01 Mart 2020

CROssBAR: Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning”, Oral presentation

Atalay M. V., Doğan T., Atalay R., Nalbat E., Rifaioğlu A. S., Ataş H., et al.
27th Conference on Intelligent Systems for Molecular Biology and 18th European Conference on Computational Biology, Basel, İsviçre, 21 - 25 Temmuz 2019

In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79 identifier

Abstract 996: In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.
AACR Annual Meeting 2019, Atlanta, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019

SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITYRELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES ASANTICANCER AGENTS

İbiş K., ÇALIŞKAN B., AKHAN GÜZELCAN E., Sinoplu E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 Temmuz 2018

SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS

ÇALIŞKAN B., Sinoplu E., İbiş K., AKHAN GÜZELCAN E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 Temmuz 2018

Metrikler

Yayın

25

Atıf (WoS)

224

H-İndeks (WoS)

5

Atıf (Scopus)

243

H-İndeks (Scopus)

5

Atıf (Scholar)

20

H-İndeks (Scholar)

1

Proje

3

Fikri Mülkiyet

3

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları